This inventor holds 1 USPTO granted patent. Top assignee: C4 Therapeutlcs, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Mark E Fitzgerald: Innovator in Targeted Degradation Therapies
Introduction
Mark E Fitzgerald is a prominent inventor based in Newton, MA (US). He has made significant contributions to the field of targeted therapies, particularly in the area of cancer treatment. His innovative work focuses on compounds that can effectively degrade specific proteins associated with cancer progression.
Latest Patents
Mark E Fitzgerald holds 1 patent for his invention titled "Compounds for targeted degradation of RET." This patent describes compounds of Formula (I) that act as protein degradation inducing moieties for the proto-oncogene tyrosine-protein kinase receptor (RET). These compounds can target both wild type and mutant forms of RET, offering potential treatment options for disorders mediated by RET protein, such as various cancers and tumors.
Career Highlights
Fitzgerald is currently associated with C4 Therapeutics, Inc., a company dedicated to advancing targeted protein degradation therapies. His work at C4 Therapeutics emphasizes the development of innovative solutions for treating cancer, showcasing his commitment to improving patient outcomes through scientific advancements.
Collaborations
Mark E Fitzgerald collaborates with notable colleagues, including James A Henderson and Christopher G Nasveschuk. These partnerships enhance the research and development efforts at C4 Therapeutics, fostering a collaborative environment that drives innovation.
Conclusion
Mark E Fitzgerald's contributions to the field of targeted degradation therapies highlight his role as a key innovator in cancer treatment. His work continues to pave the way for new therapeutic options that may significantly impact patient care.